11 completed, 9 terminated, 2 withdrawn, 1 recruiting. 17 Phase 2, 5 Phase 3, 4 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 9, Terminated 6, Recruiting 1, Withdrawn 1 |
| Phase 3 | 5 | Completed 2, Terminated 2, Unknown 1 |
| Phase 1 | 4 | Completed 2, Terminated 1, Withdrawn 1 |
| Phase 4 | 1 | Withdrawn 1 |
Follow camostat: new trials by email Literature Review of camostat trials Research Report on camostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect Camostat for Kidney Protection in Chronic Kidney Disease Camostat Mesylate - Chronic Kidney Disease(CKD) | Phase 2 | Recruiting | Odense University Hospital | 40 | 2024-11-21 | 2025-01-27 |
| Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation Camostat mesylate - Fontan Operation, Protein-Losing Enteropathy | Phase 2 | Completed | Seoul National University Hospital | 19 | 2022-10-03 | 2024-12-03 |
| The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications Camostat Mesylate, Microcrystalline Cellulose, NF - Coagulopathy, Cardiovascular Complication | Phase 1 / Phase 2 | Withdrawn | Yale University | 2021-11-01 | 2022-05-18 | |
| The DAWN Antivirals Trial for Ambulatory COVID-19 Patients Camostat, Placebo, Molnupiravir - Covid19, SARS-CoV Infection | Phase 3 | Terminated | KU Leuven | 44 | 2021-06-15 | 2022-10-03 |
| COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol Camostat, Placebo - Covid19 | Phase 2 | Terminated | Stanford University | 2 | 2021-04-23 | 2023-06-28 |
| COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol Acebilustat, Camostat - Covid19 | Phase 2 | Completed | Stanford University | 122 | 2021-04-23 | 2023-06-28 |
| Camostat With Bicalutamide for COVID-19 Camostat Mesilate, Bicalutamide 150 mg - Covid19, SARS-CoV Infection | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 6 | 2021-02-03 | 2023-10-06 |
| Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat Niclosamide + Camostat, Placebo - Covid19 | Phase 2 | Terminated | Charité Research Organisation GmbH | 4 | 2021-02-03 | 2021-12-09 |
| Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals Convalescent plasma, Camostat Mesilate, Placebo for Camostat Mesilate - Corona Virus Infection, SARS-CoV-2 Infection | Phase 2 | Completed | Heinrich-Heine University, Duesseldorf | 22 | 2021-01-08 | 2022-02-10 |
| Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients Camostat Mesilate, Placebo, Standard of Care Treatment - Covid19 | Phase 2 | Completed | Stanford University | 49 | 2020-12-19 | 2022-06-10 |
| CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients Camostat Mesylate, Placebo - Covid19 | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 70 | 2020-12-03 | 2022-02-10 |
| Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT) Camostat Mesilate, Placebo - COVID-19 | Phase 2 | Completed | Sagent Pharmaceuticals Inc. | 295 | 2020-11-09 | 2022-01-18 |
| A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19) FOY-305, Placebo - SARS-CoV-2 Infection (COVID-19) | Phase 3 | Completed | Ono Pharmaceutical Co., Ltd. | 155 | 2020-11-09 | 2024-04-05 |
| The Potential of Camostat in COVID-19 Camostat, Placebo - Covid19 | Phase 2 | Terminated | University Hospital, Ghent | 108 | 2020-11-04 | 2024-08-09 |
| Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients Camostat Mesilate, Artemisia Annua Leaf - Covid19, Diabetes | Phase 2 | Terminated | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 246 | 2020-10-05 | 2021-06-21 |
| A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1) Camostat - COVID-19 Infection | Phase 2 | Terminated | Cancer Research UK | 34 | 2020-09-23 | 2023-12-11 |
| ACTIV-2: A Study for Outpatients With COVID-19 bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV) - Coronavirus, Covid19 | Phase 2 / Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 4044 | 2020-08-19 | 2024-08-02 |
| Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19 Camostat Mesilate, Standard of Care - Severe Acute Respiratory Syndrome | Phase 2 | Completed | Alan Bryce | 100 | 2020-07-28 | 2024-11-12 |
| Multiple-dose Study of FOY-305 in Japanese Healthy Adult Male Subjects FOY-305 - Healthy Volunteers | Phase 1 | Completed | Ono Pharmaceutical Co., Ltd. | 14 | 2020-07-01 | 2024-04-09 |
| Camostat Mesylate in COVID-19 Outpatients Camostat Mesilate, Placebo - COVID-19 | Phase 2 | Completed | Yale University | 70 | 2020-06-09 | 2022-03-24 |
Showing 20 of 24. Sign in to see all of them.
COVID-19 (18) · Coronavirus Infections (5) · Severe Acute Respiratory Syndrome (4) · Virus Diseases (2) · Albuminuria (1) · Coronaviridae Infections (1) · Diabetes Mellitus (1) · Hemostatic Disorders (1) · Hypertension (1) · Nidovirales Infections (1) · Obesity (1) · Pneumonia, Viral (1) · Protein-Losing Enteropathies (1) · Proteinuria (1) · RNA Virus Infections (1)
Stanford University (3) · Heinrich-Heine University, Duesseldorf (2) · Ono Pharmaceutical Co., Ltd. (2) · Yale University (2) · Alan Bryce (1) · Assistance Publique - Hôpitaux de Paris (1) · Cancer Research UK (1) · Charité Research Organisation GmbH (1) · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (1) · KU Leuven (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Odense University Hospital (1) · Sagent Pharmaceuticals Inc. (1) · Seoul National University Hospital (1) · Sheba Medical Center (1)
United States (9) · Belgium (2) · Denmark (2) · Germany (2) · Japan (2) · Mexico (2) · Argentina (1) · Brazil (1) · Canada (1) · France (1) · Guatemala (1) · Israel (1) · Philippines (1) · Puerto Rico (1) · South Africa (1)
Chaitan Khosla, PhD (2) · Julie Parsonnet, MD (2) · Alan H Bryce, M.D. (1) · Arya Mani, MD (1) · Catherine H Marshall, MD/MPH (1) · Claus Bistrup, MD, Professor (1) · David Smith, MD, MAS (1) · Geoffrey Chupp, M.D. (1) · Gi Beom B Kim (1) · Haley Hedlin, PhD (1) · Jose G Gotes Palazuelos, MD (1) · Joseph Vinetz, M.D. (1) · Kevin Dhaliwal, Professor (1) · Manisha Desai, PhD (1)
PMID 34473343, PMID 15030519, PMID 15885816, PMID 17276373, PMID 18434652, PMID 18752857, PMID 19190233, PMID 21423999, PMID 22496216, PMID 23412700, PMID 25666761, PMID 25816117, PMID 26166259, PMID 28325826, PMID 28880869, PMID 29414327, PMID 30668322, PMID 31986264, PMID 32031570, PMID 32075786, PMID 32108857, PMID 32109013, PMID 32112977, PMID 32142651, PMID 32167524, PMID 32215618, PMID 32298251, PMID 32338708, PMID 32584326, PMID 33903855, PMID 34001215, PMID 34981077, PMID 35132421, PMID 35412356, PMID 35713300, PMID 35793677, PMID 35797235, PMID 35803469, PMID 35995785, PMID 36163020, PMID 36210483, PMID 36289399, PMID 36301549, PMID 36378539, PMID 36467293, PMID 36661240, PMID 36802755, PMID 36996150, PMID 37068272, PMID 37099295
2023 (1)